AMRX (STOCKS)
Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.270000
-0.390000 (-2.21%)
Prev close: $17.660000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Chintu Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,516.84M
- Employees
- 8,100
- P/E (TTM)
- 36.85
- P/B (TTM)
- 170.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.30 | $0.23 | +0.0741 | +32.80% |
|
Mar 2026 (Q1)
|
$0.27 | $0.17 | +0.0966 | +55.71% |
|
Dec 2025 (Q4)
|
$0.21 | $0.19 | +0.0217 | +11.52% |
|
Sep 2025 (Q3)
|
$0.17 | $0.14 | +0.0297 | +21.17% |
Financial Statements
| Revenues | $3.12B |
| Benefits Costs and Expenses | $2.92B |
| Cost Of Revenue | $1.89B |
| Costs And Expenses | $2.92B |
| Gross Profit | $1.23B |
| Nonoperating Income/Loss | -$252.74M |
| Operating Expenses | $771.87M |
| Selling, General, and Administrative Expenses | $571.86M |
| Research and Development | $175.57M |
| Other Operating Expenses | $24.44M |
| Operating Income/Loss | $453.92M |
| Income/Loss From Continuing Operations After Tax | $215.32M |
| Income/Loss From Continuing Operations Before Tax | $201.18M |
| Income Tax Expense/Benefit | -$14.14M |
| Net Income/Loss | $215.32M |
| Net Income/Loss Attributable To Noncontrolling Interest | $57.96M |
| Net Income/Loss Attributable To Parent | $157.36M |
| Net Income/Loss Available To Common Stockholders, Basic | $157.36M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.50 |
| Diluted Earnings Per Share | $0.49 |
| Basic Average Shares | 949,760,000 |
| Diluted Average Shares | 982,890,000 |
| Assets | $3.78B |
| Current Assets | $1.95B |
| Inventory | $677.95M |
| Other Current Assets | $1.27B |
| Noncurrent Assets | $1.83B |
| Fixed Assets | $456.88M |
| Intangible Assets | $587.83M |
| Other Non-current Assets | $784.61M |
| Liabilities | $3.66B |
| Current Liabilities | $883.19M |
| Noncurrent Liabilities | $2.78B |
| Long-term Debt | $2.57B |
| Other Non-current Liabilities | $205.89M |
| Equity | $33.02M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $33.02M |
| Temporary Equity | $83.96M |
| Liabilities And Equity | $3.78B |
| Net Cash Flow From Operating Activities | $200.78M |
| Net Cash Flow From Operating Activities, Continuing | $200.78M |
| Net Cash Flow From Investing Activities | -$212.37M |
| Net Cash Flow From Investing Activities, Continuing | -$212.37M |
| Net Cash Flow From Financing Activities | $69.63M |
| Net Cash Flow From Financing Activities, Continuing | $69.63M |
| Exchange Gains/Losses | -$2.09M |
| Net Cash Flow | $55.95M |
| Net Cash Flow, Continuing | $58.04M |
| Comprehensive Income/Loss | $154.13M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $154.13M |
| Other Comprehensive Income/Loss | -$61.19M |
| Other Comprehensive Income/Loss Attributable To Parent | -$3.24M |